{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-23-000134","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.076553+00:00","generated_at":"2026-06-07T08:18:34.180279+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Senti Bio receives FDA IND clearance for SENTI-202 CAR-NK therapy for AML","bullets":["FDA cleared IND for SENTI-202, an off-the-shelf CAR-NK cell therapy targeting CD33/FLT3 hematologic malignancies including AML.","Phase 1 trial expected to treat first patient in Q2 2024 at multiple US and Australia sites.","Initial efficacy data expected by year-end 2024; durability data expected in 2025.","Trial evaluates two dose levels (1 or 1.5 billion cells) with three weekly doses after lymphodepletion and optional continuation cycles.","Manufacturing expenses for Phase 1 largely prepaid through existing GeneFab agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-23-000134","json":"https://secwatch.observer/filing/0001854270-23-000134.json","markdown":"https://secwatch.observer/filing/0001854270-23-000134.md","text":"https://secwatch.observer/filing/0001854270-23-000134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000134/0001854270-23-000134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000134/snti-20231222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:18:34.180279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}